Biopharmaceutical Core
A Biopharmaceutical Company Developing Advanced Cell Therapeutics (ATMP)
From discovery and manufacturing to regulated patient access through our integrated clinical network.
Your Global ATMP Licensing Partner
United Kingdom, Japan, United Arab Emirates
ATMP License Acquition History
Our London and Tokyo hubs are integral to our platform, connecting clinical operations, data generation, and therapeutic development within a unified biopharmaceutical framework.
Together, these hubs create a continuous feedback loop between clinical practice and therapeutic development.
London — Translational R&D and Therapeutic Development
- Platform for clinical-to-development translation
- Early-stage validation and regulatory alignment
- Showcase for advanced cell-based therapeutics
- Integration with global scientific and regulatory ecosystem
Tokyo — Premium Clinical Access and Data Generation Hub
- Access to high-value patient populations in Asia
- Longitudinal data capture and real-world evidence generation
- Standardized clinical protocols and follow-up systems
- Foundation for scalable therapeutic validation
Helene's Development Focus
Autologous Cell-Based Therapeutics
Development of patient-derived cell therapeutics leveraging clinical insight and controlled processing to enable reproducible and regulated treatment modalities.
Allogeneic Cell Therapeutics
Development of scalable, donor-derived cell therapeutics designed for standardization, manufacturing efficiency, and broader clinical application.
Target Indications / Stage
Focused development across selected indications, supported by clinical data, defined development stages, and a structured path toward regulatory approval.
Pipelines
Advanced Therapy Medical Product (ATMP)
Regulated therapeutic development
Development of advanced cell-based therapeutics within regulatory frameworks, focusing on safety, efficacy, and scalable clinical application.
Manufacturing & Quality Control
Standardized and reproducible production
End-to-end cell processing and manufacturing capabilities supported by standardized protocols, quality control systems, and defined release criteria to ensure consistency and reproducibility.
Global Clinical Network
Data-driven clinical infrastructure
Integrated clinical infrastructure enabling patiet access, longitudinal data collection, and real-world evidence generation to support therapeutic development.
Cell Banking
Traceability and long-term scalability
Establishment and management of cell banking systems to support traceability, long-term storage, and scalable therapeutic development.
Subsidiary Pharmaceutical Labs and medical centers
Biopharmaceutical Approach to Cell Therapies
What is your approach to cell-based therapeutics?
We develop cell-based therapeutics through an integrated biopharmaceutical platform combining autologous and allogeneic approaches.
Our strategy leverages clinical experience to inform therapeutic design, enabling the transition from treatment-based applications to standardized, scalable cell therapeutics. By integrating clinical insights with manufacturing and development capabilities, we aim to establish reproducible and regulated therapeutic modalities.
How does your clinical network support development?
Our global clinical network functions as a core infrastructure for patient access, data acquisition, and therapeutic validation.
Through controlled clinical environments, we are able to capture longitudinal patient data, monitor safety and outcomes, and generate real-world evidence. This continuous feedback loop directly informs our development pipeline, accelerating optimization and supporting regulatory pathways.
How do you ensure quality and consistency?
We maintain strict control over the entire manufacturing process, from cell sourcing to final product release.
Our system incorporates standardized protocols, quality control (QC) testing, and defined release criteria to ensure consistency and safety. Additionally, we implement full traceability through chain of identity (CoI) and chain of custody (CoC) systems, ensuring each product is accurately tracked throughout its lifecycle.
What is your regulatory strategy?
We pursue a region-specific regulatory strategy aligned with advanced therapy medicinal product (ATMP) frameworks and equivalent regulatory pathways.
Our approach emphasizes early clinical validation, structured data generation, and alignment with regulatory expectations in each jurisdiction. By integrating clinical practice with development, we aim to bridge the gap between treatment applications and formal therapeutic approval.
How is data utilized in your platform?
Data is a central asset within our platform.
We systematically collect and analyze longitudinal clinical data to generate real-world evidence, support scientific publications, and inform both clinical and commercial strategies. This data-driven approach enhances our ability to refine therapeutic protocols, demonstrate value, and support pricing and reimbursement discussions.
.
What differentiates your platform?
Our key differentiation lies in the integration of development, manufacturing, and global clinical infrastructure within a single platform.
Unlike traditional models where these functions are separated, our approach enables rapid iteration, efficient data utilization, and direct patient access. This integrated structure allows us to accelerate the translation of cell-based therapies from concept to clinical application and beyond.
Award
Recognized globally for excellence, we hold numerous certifications and awards, reinforcing trust in our innovative solutions.
Mission Statement
See our mission
Invester Relations
Jump to IR Page
Helene History
See past history
Business Locations
See our business locations
Company Profile
Company profileCellular Innovation
Building the Future of Cell Therapeutics
We are building a fully integrated biopharmaceutical platform to advance the development of cell-based therapeutics, combining clinical access, cell processing, and data-driven development within a unified system. Unlike traditional models where clinical practice, manufacturing, and therapeutic development operate independently, our approach connects these functions into a continuous and iterative cycle. Through our global clinical network, we gain direct access to patients and longitudinal clinical data, enabling real-world insights into safety, efficacy, and therapeutics outcomes. These insights are systematically integrated into our development process, informing the optimization of cell processing protocols, quality control standards, and therapeutic design. By maintaining control over both clinical and manufacturing environments, we are able to standardize procedures, ensure reproducibility, and build a foundation for scalable and regulated therapeutic products. Our platform is designed not only to deliver therapeutics, but to transform clinical experience into validated, data-supported therapeutics. This integrated structure allows us to accelerate development timelines, reduce fragmentation across the value chain, and create a sustainable pathway from clinical application to approved cell-based therapies.
Trusted Leaders in BioTech Company
Our London and Tokyo hubs play critical roles in our biopharmaceutical platform, enabling clinical insight, data acquisition, and the advancement of cell-based therapeutic development.
Dr. Matsuoka, MD, PhD, MBA
Founder & Group CEO
Medicine, Keio University
PhD in Medicine (Stem cell Research)
Timi Ellinas, PhD(cand)
CEO of Helene Therapeutics London
Biotech, King's college London
Dr. Christina Philippeos, PhD
Chief Science Officer
PhD in Cellular Biology, King's college London
Dr. Nassos Alevizopoulos, Ph.D
Drug Development Consultant
PhD in Molecular Biology, University of Lausanne.
Dr. Luca Cannizzaro
Proteomics Consultant
MSc Pharmacology, PhD Biochemistry
Mr. Takahashi, CPA
Group CFO
Tokyo Tech University
Japan CPA, USCPA
Mr. Harry Shin
Asia Regional COO
British Columbia University
Dr. Nakamura, PhD
CSO in Japan
PhD in Biotechnology
Advisory Board
Mr. Hosokawa, Esq
Former Minster of Health in Japan
Lawyer
Professor. Gupta Ravi, MBBS, PhD
Professor of MIcrobiology in Cambridge University
Professor. Nakatsuji, PhD
Emiratus Professor of Kyoto University. Former Stem cell Institution in Kyoto Uni.
Professor. Fiona Watt, PhD
Director of European Molecular Biology Organization
Mr. Kamohara
Former Undersecretary of Ministry of Health, Labour and Welfare
Mr. Araki, Esq
Morgan Lewis Legal firm Tokyo
Attorney-at-Law, New York
Trusted Doctors in the Stem Cell Clinics
Our expert team in Tokyo,UK and UAE delivers stem cell treatments, advancing health outcomes with precision and dedication.
Dr. Androulakakis, MBBS
[UK-London]
Consultant Plastic Surgeon
Dr. Botchey, MBBS
[UK-London]
Stem cell treatment specialist in Sport medicine
Dr. Nana, MD
[Japan - Tokyo]
Board Certified Surgeon
Gastrointestinal surgeon
Dr. Kuroki, MD, PhD
[Japan - Hiroshima]
Board Certified Surgeon
Cardiovascular surgeon
Dr. Itohara, MD
[JAPAN-Tokyo]
Board Certified Surgeon
Cardiovascular surgeon
Dr. Ueda, MD
[Tokyo] [Abu Dhabi]
Board Certified Surgeon
Thoracic surgeon
Dr. Hara, MD
[Tokyo] [Dubai]
Board certified OB/GYN
Dr. Terakawa, MD, PhD
[Tokyo] [Abu Dhabi]
Board Certified NeuroSurgeon
Dr. Sana, MBBS
MBBS, London
Dr. Fatemah El‑Gapaty
[Dubai]
Specialist General Surgeon
Dr. Athar Hassan
[Abu Dhabi]
General Physician
Contact Us for Helene Therapeutics - business inquries
Reach out for a business inqury. We're here to assist you.
Contact for your stem cell treatment
Send us a message and our clinic proffetionals get back to you as soon as we can.